Results 251 to 260 of about 245,924 (389)

Incorporating Multiple Imputation Into Tanezumab Dose–Response Modeling of WOMAC Pain CFB Across Six Randomized Placebo‐Controlled Phase 3 Trials

open access: yesCPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Multiple imputation is increasingly being used to deal with missing data in clinical trials. It is a simulation approach leading to multiple analyses of a pre‐defined number of datasets. For a pre‐defined statistical model, this is relatively straightforward, but for model development as typically conducted in Pharmacometrics, it is unclear ...
Martin Boucher   +2 more
wiley   +1 more source

Bimodal Dissolving Microneedles with Nanoparticle Coating and Encapsulation for Extended Dual‐Drug Delivery

open access: yesSmall, EarlyView.
A novel bimodal coated‐dissolving microneedle system is developed for extended transdermal delivery of diclofenac and dexamethasone nanoparticles. The formulation enables high drug loading, efficient skin penetration, and sustained release over 72 h, offering a minimally invasive, self‐administered therapy to improve osteoarthritis treatment by ...
Mingshan Li   +8 more
wiley   +1 more source

Curcumin ameliorates hyperuricemia and gout‐induced damage via modulating the ROS‐dependent NEK7‐NLRP3 inflammasome activation

open access: yesSmart Molecules, EarlyView.
Curcumin inhibits the ROS/NEK7‐NLRP3 inflammasome pathway by reducing reactive oxygen species (ROS) levels and disrupting the association of the NEK7‐NLRP3 complex. These combined effects of curcumin result in suppression of the GSDMD‐N pyroptotic pore formation and subsequent reduction of IL‐1β release.
Zhengtian Zhao   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy